KAHR medical
company
About
KAHR Medical develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases.
- 1 - 10
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $3M
- Industries
- Biotechnology,Medical,Pharmaceutical
- Founded date
- Jan 1, 2005
- Number Of Employee
- 1 - 10
- Operating Status
- Active
KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment options for cancer and autoimmune disorders.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$67.50M
KAHR medical has raised a total of
$67.50M
in funding over 2 rounds. Their latest funding was raised on
Jun 16, 2021 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 16, 2021 | Series Unknown | $46.50M | 1 | — | — | Detail |
| Feb 25, 2020 | Series Unknown | $18M | 1 | — | — | Detail |
| Apr 14, 2011 | Series Unknown | $3M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
KAHR medical is funded by 2 investors.
Pavilion Capital
and Sanofi
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Pavilion Capital
|
— | Series Unknown |
Sanofi
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
